The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Breast Cancer after Prophylactic Bilateral Mastectomy in Women with a BRCA1 or BRCA2 Mutation
Open accessAbstract
BACKGROUND: Women with a BRCA1 or BRCA2 mutation have a high risk of breast cancer and may choose to undergo prophylactic bilateral total mastectomy. We investigated the efficacy of this procedure in such women. METHODS: We conducted a prospective study of 139 women with a pathogenic BRCA1 or BRCA2 mutation who were enrolled in a breast-cancer surveillance program at the Rotterdam Family Cancer Clinic. At the time of enrollment, none of the women had a history of breast cancer. Seventy-six of these women eventually underwent prophylactic mastectomy, and the other 63 remained under regular surveillance. The effect of mastectomy on the incidence of breast cancer was analyzed by the Cox proportional-hazards method in which mastectomy was modeled as a time-dependent covariate. RESULTS: No cases of breast cancer were observed after prophylactic mastectomy after a mean (+/-SE) follow-up of 2.9+/-1.4 years, whereas eight breast cancers developed in women under regular surveillance after a mean follow-up of 3.0+/-1.5 years (P=0.003; hazard ratio, 0; 95 percent confidence interval, 0 to 0.36). The actuarial mean five-year incidence of breast cancer among all women in the surveillance group was 17+/-7 percent. On the basis of an exponential model, the yearly incidence of breast cancer in this group was 2.5 percent. The observed number of breast cancers in the surveillance group was consistent with the expected number (ratio of observed to expected cases, 1.2; 95 percent confidence interval, 0.4 to 3.7; P=0.80). CONCLUSIONS: In women with a BRCA1 or BRCA2 mutation, prophylactic bilateral total mastectomy reduces the incidence of breast cancer at three years of follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies on PM consistently show a risk reduction of breast cancer of at least 90% [1,2]”
From Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy (2009) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which has been shown to reduce the incidence of breast cancer by approximately 90% [57-59]”
From Screening, Risk Reduction Strategies, and Clinical Management of Unaffected Carriers of BRCA1 or BRCA2 Pathogenic Variants (2026) · cites this paper as [58]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J. J., Shattuck-Eidens, D. M., Futreal, P. A., Harshman, K., Tavtigian, S. V., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,069
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M. T., Cronin, W. M., Vogel, V. G., Robidoux, A., Dimitrov, N. S., Atkins, J. N., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,450
Identification of the breast cancer susceptibility gene BRCA2
Wooster, R., Bignell, G. R., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S. G., Gumbs, C. E., Micklem, G., et al. (1995) · Nature · doi:10.1038/378789a0 · Cited by 3,645
Ford, D., Easton, D., Stratton, M. R., Narod, S., Goldgar, D., Devilee, P., Bishop, D., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · American Journal of Human Genetics · doi:10.1086/301749 · Cited by 2,766
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Struewing, J., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L., & Tucker, M. A. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362001 · Cited by 2,399
Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer
Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P. G., Petty, P. M., Sellers, T. A., Johnson, J. L., McDonnell, S. K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400201 · Cited by 1,428
Burke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955
Lerman, C., Narod, S., Schulman, K., Hughes, C., Gomez-Caminero, A., Bonney, G., Gold, K., Trock, B., Main, D., Lynch, J., et al. (1996) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.275.24.1885 · Cited by 840
BRCA1 Testing in Families With Hereditary Breast-Ovarian Cancer
Lerman, C. E. (1996) · JAMA · doi:10.1001/jama.1996.03530480027036 · Cited by 826
Breast Cancer Risk After Bilateral Prophylactic Oophorectomy in BRCA1 Mutation Carriers
Rebbeck, T. R., Levin, A. M., Eisen, A. F., Snyder, C., Watson, P. A., Cannon‐Albright, L., Isaacs, C. J., Olopade, O., Garber, J. E., Godwin, A. K., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.17.1475 · Cited by 670
Kuhl, C. K., Schmutzler, R., Leutner, C., Kempe, A., Wardelmann, E., Hocke, A., Maringa, M., Pfeifer, U., Krebs, D., & Schild, H. (2000) · Radiology · doi:10.1148/radiology.215.1.r00ap01267 · Cited by 584
Narod, S., Brunet, J., Ghadirian, P., Robson, M., Heimdal, K., Neuhausen, S., Stoppa-Lyonnet, D., Lerman, C., Pasini, B., Ríos, P. D. L., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03258-x · Cited by 557
Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
Bergman, L., Beelen, M. L., Gallee, M. P. W., Hollema, H., Benraadt, J., & van Leeuwen, F. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02677-5 · Cited by 541
Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1
Verhoog, L., Brekelmans, C., Seynaeve, C., van den Bosch, L., Dahmen, G., van Geel, A., Tilanus-Linthorst, M., Bartels, C., Wagner, A., van den Ouweland, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07065-7 · Cited by 452
Self-citationComplications Leading to Surgery after Breast Implantation
Gabriel, S. E., Woods, J. E., O’Fallon, W. M., Beard, C. M., Kurland, L. T., & Melton, L. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361001 · Cited by 446
BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients
Petrij-Bosch, A., Peelen, T., van Vliet, M., van Eijk, R., Olmer, R., Drüsedau, M., Hogervorst, F. B. L., Hageman, S., Arts, P. J. W., Ligtenberg, M. J. L., et al. (1997) · Nature Genetics · doi:10.1038/ng1197-341 · Cited by 432
Self-citationWhittemore, A. S., Gong, G. D., & Itnyre, J. (1997) · PubMed · Cited by 383
Rapid detection of BRCA1 mutations by the protein truncation test
Hogervorst, F., Cornelis, R., Bout, M., van Vliet, M., Oosterwijk, J., Olmer, R., Bakker, B., Klijn, J., Vasen, H., Meijers-Heijboer, H., et al. (1995) · Nature Genetics · doi:10.1038/ng0695-208 · Cited by 341
Self-citationPresymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer, E. J., Verhoog, L., Brekelmans, C., Seynaeve, C., Tilanus-Linthorst, M., Wagner, A., Dukel, L., Devilee, P., van den Ouweland, A. V. D., van Geel, A. V., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02347-3 · Cited by 328
Self-citationFrost, M. H. (2000) · JAMA · doi:10.1001/jama.284.3.319 · Cited by 325
Brekelmans, C. T. M., Seynaeve, C., Bartels, C. C. M., Tilanus‐Linthorst, M. M. A., Meijers-Heijboer, E. J., Crépin, C., van Geel, A. N., Menke, M., Verhoog, L. C., van den Ouweland, A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.924 · Cited by 306
Self-citationSurvival in hereditary breast cancer associated with germline mutations of BRCA2.
Verhoog, L., Brekelmans, C., Seynaeve, C., Dahmen, G., van Geel, A. V., Bartels, C., Tilanus-Linthorst, M., Wagner, A., Devilee, P., Halley, D., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3396 · Cited by 197
Self-citationPredictors of and Satisfaction with Bilateral Prophylactic Mastectomy
Stefanek, M. E., Helzlsouer, K. J., Wilcox, P. M., & Houn, F. (1995) · Preventive Medicine · doi:10.1006/pmed.1995.1066 · Cited by 177
Hatcher, M. B. (2001) · BMJ · doi:10.1136/bmj.322.7278.76 · Cited by 160
Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer.
Eisen, A., Rebbeck, T., Wood, W., & Weber, B. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1980 · Cited by 148
The woman at increased risk for breast cancer: evaluation and management strategies
Bilimoria, M. M., & Morrow, M. (1995) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.45.5.263 · Cited by 111
Inheritance of Proliferative Breast Disease in Breast Cancer Kindreds
Skolnick, M. H., Cannon‐Albright, L., Goldgar, D. E., Ward, J. H., Marshall, C. J., Schumann, G. B., Hogle, H. H., McWhorter, W. P., Wright, E. C., Tran, T. D., et al. (1990) · Science · doi:10.1126/science.2270486 · Cited by 100
Patient regrets after bilateral prophylactic mastectomy
Borgen, P., Hill, A., Tran, K. N., Zee, K. V., Massie, M., Payne, D., & Biggs, C. (1998) · Annals of Surgical Oncology · doi:10.1007/bf02303829 · Cited by 93
Khurana, K. K., Loosmann, A., Numann, P. J., & Khan, S. A. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0378-pmpfih · Cited by 51
Screening for BRCA2 mutations in 81 Dutch breast–ovarian cancer families
Peelen, T., van Vliet, M., Bosch, A. M., Bignell, G. R., Vasen, H. F. A., Klijn, J. G. M., Meijers-Heijboer, H. E. J., Stratton, M. R., van Ommen, G. B., Cornelisse, C. J., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0892 · Cited by 46
Self-citationShould prophylactic surgery be used in women with a high risk of breast cancer?
Klijn, J. G. M. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00360-2 · Cited by 34
Self-citationIdentification of the breast cancer susceptibility gene BRCA2
Wooster, R. F., Bignell, G. R., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S. G., Gumbs, C. E., Michlem, G., et al. (1996) · Nature · doi:10.1038/379749a0 · Cited by 30
MRI screening for breast cancer in women with high familial risk
Kriege, M., Brekelmans, C. T. M., Boetes, C., Rutgers, E. J. T., Oosterwijk, J. C., Tollenaar, R. A. �. �., Manoliu, R. A., Holland, R. H., de Koning, H. J., Klijn, J. G. M., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 5
Self-citation
Research works printed but not linked: 4
- Whittemore AS, 1997, Am J Hum Genet, 60, 496
- Hartmann LC, 2000, Proc Am Assoc Cancer Res, 41, 222
- Kriege M, 2000, Eur J Cancer, 36, S137
- Zion SM, 2000, Prog Proc Am Soc Clin Oncol, 19, 441a
Cited by
Sorted by citations
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
King, M.-C., Marks, J. H., & Mandell, J. B. (2003) · Science · doi:10.1126/science.1088759 · Cited by 2,229
Kriege, M., Brekelmans, C. T. M., Boetes, C., Besnard, P. E., Zonderland, H. M., Obdeijn, I. M., Manoliu, R. A., Kok, T., Peterse, H. L., Tilanus‐Linthorst, M. M. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031759 · Cited by 1,686
“Posthysterectomy 3 (1) 48 (5) 24 (5) 75 (4)”
Self-citationDomchek, S. M. (2010) · JAMA · doi:10.1001/jama.2010.1237 · Cited by 1,494
“Risk-reducing mastectomy is a highly effective strategy for breast cancer risk reduction.(20,21) In our prospec-”
Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2Mutation
Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M. L., Hudis, C. A., Ellis, N. A., Boyd, J. A., Borgen, P. I., Barakat, R. R., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020119 · Cited by 1,250
Kuhl, C. K., Schrading, S., Leutner, C., Morakkabati-Spitz, N., Wardelmann, E., Fimmers, R., Kuhn, W. C., & Schild, H. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.4960 · Cited by 1,148
“BRCA2 mutations compared with so-called watchful waiting.(13-16) Nonetheless, the perceived mutilating effects of mastectomy make the decision for surgical prevention difficult, and current national guidelines do not recommend it as standard management.”
Background
Metadata
- Authors
- Meijers-Heijboer, H., van Geel, B., van Putten, W. L. J., Henzen-Logmans, S. C., Seynaeve, C., Menke-Pluymers, M. B. E., Bartels, C. C. M., Verhoog, L. C., van den Ouweland, A. M. W., Niermeijer, M. F., Brekelmans, C. T. M., & Klijn, J. G. M.
- Affiliations
- Erasmus MC (NL)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-07-19
- Volume
- 345
- Issue
- 3
- Pages
- 159-164
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2046809735
- Cited by
- 973
- References
- 33
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 14 · 2023: 18 · 2022: 18 · 2021: 24 · 2020: 23 · 2019: 30 · 2018: 21 · 2017: 37 · 2016: 42 · 2015: 28 · 2014: 34 · 2013: 29 · 2012: 42
- FWCI
- 35.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (acceptedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Keywords
- breast cancer, bilateral prophylactic mastectomy, BRCA1 mutation, BRCA2 mutation, hereditary breast cancer, breast cancer incidence, breast cancer surveillance, genetic susceptibility to cancer
- MeSH terms
- Adult, Breast Neoplasms, Female, Humans, Middle Aged, Mutation, Neoplasm Proteins, Prospective Studies, Transcription Factors, Mastectomy, Simple, Proportional Hazards Models, Genes, BRCA1, BRCA2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
